A $1 Billion Startup Just to Get Your Prescription Approved? Welcome to American Healthcare.

A New York startup has hit a $1B valuation by solving a problem the NHS quietly solved for us decades ago — and that contrast tells us everything.

Introduction

Living in the UK, I have never once had to phone my GP surgery to chase a pharmacist, who then has to call my insurer, who then has to verify with a different department whether my prescription is actually approved — before I can collect the tablets my doctor already decided I needed.

That sequence sounds almost satirical. In the US, it's Tuesday.

Tandem Technology Inc., a New York-based AI startup, just hit a $1 billion valuation doing one thing: automating the bureaucratic nightmare that sits between an American doctor writing a prescription and a patient actually receiving it. That a company can reach unicorn status solving this single problem says less about the cleverness of the technology and more about just how broken the system it's fixing really is.

What Tandem Actually Does

Tandem builds AI tools that handle what the healthcare industry calls "prior authorisations" — a process where insurers require doctors to submit paperwork justifying a prescription before they'll agree to cover it. On paper, it's a cost-control mechanism. In practice, it's a delay machine that keeps medication out of patients' hands while administrators drown in follow-up calls.

Tandem automates those calls, those forms, and those follow-ups. The platform is free for both healthcare providers and patients, with the business model expected to lean on biopharma partnerships instead.

It's backed by Thrive Capital and General Catalyst, has raised $137 million to date including a fresh $100 million Series B led by Accel, and expects millions of patients on its platform by 2026.

The View From Outside

From where I'm standing — and from where most people in the UK, Ireland, or anywhere with a functioning public health system are standing — this is a genuinely strange thing to build a billion-dollar company around.

Not because the technology isn't impressive. It clearly is. But because the problem it solves is entirely manufactured. Prior authorisations exist because the American insurance model creates a financial incentive to delay or deny coverage. Tandem doesn't challenge that model. It just greases the wheels so the machine runs a little faster.

That's not a criticism of Tandem — they're doing something genuinely useful for patients who are stuck in that system right now. But it's worth naming what's actually happening: investors are pouring $100 million into making a bad system more tolerable, rather than fixing the system itself.

Why It Still Matters (Even Here)

For all that, there's something worth watching in how Tandem is approaching healthcare administration with AI. The NHS isn't immune to paperwork. GP referrals, prescription queries, appointment follow-ups — there's no shortage of administrative friction in British or Irish healthcare either, even if it looks nothing like the American version.

The idea that AI can absorb the back-and-forth between providers, systems, and patients — without adding cost for the people who need care — is a model worth paying attention to. If Tandem proves it works at scale in the US, expect similar tools aimed at NHS trusts and GP networks within a few years.

The problem being solved will look different. But the underlying logic — AI handling the administrative layer so clinicians and patients don't have to — translates.

Key Takeaways

• Tandem Technology has reached a $1B valuation by automating prescription prior authorisations in the US, raising $100M in a Series B led by Accel.

• The platform is free for providers and patients, with revenue expected through biopharma partnerships — not user fees.

• For those outside the US, this is a reminder that healthcare admin inefficiency isn't uniquely American; it's just most visible there. The AI tools being built to fix it will travel.